"1748-3395"[Journal] - Search Results

Year	Number of Results
2006	51
2007	210
2008	210
2009	244
2010	224
2011	202
2012	176
2013	244
2014	263
2015	283
2016	280
2017	273
2018	275
2019	258
2020	231
2021	251
2022	267
2023	36

1

Extracellular vesicles as a next-generation drug delivery platform.

Herrmann IK, Wood MJA, Fuhrmann G. Herrmann IK, et al. Nat Nanotechnol. 2021 Jul;16(7):748-759. doi: 10.1038/s41565-021-00931-2. Epub 2021 Jul 1. Nat Nanotechnol. 2021. PMID: 34211166 Review.

2

The current landscape of nucleic acid therapeutics.

Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, van der Meel R. Kulkarni JA, et al. Nat Nanotechnol. 2021 Jun;16(6):630-643. doi: 10.1038/s41565-021-00898-0. Epub 2021 May 31. Nat Nanotechnol. 2021. PMID: 34059811 Review.

3

Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells.

Saha T, Dash C, Jayabalan R, Khiste S, Kulkarni A, Kurmi K, Mondal J, Majumder PK, Bardia A, Jang HL, Sengupta S. Saha T, et al. Nat Nanotechnol. 2022 Jan;17(1):98-106. doi: 10.1038/s41565-021-01000-4. Epub 2021 Nov 18. Nat Nanotechnol. 2022. PMID: 34795441

4

A pyroptosis nanotuner for cancer therapy.

Chen B, Yan Y, Yang Y, Cao G, Wang X, Wang Y, Wan F, Yin Q, Wang Z, Li Y, Wang L, Xu B, You F, Zhang Q, Wang Y. Chen B, et al. Nat Nanotechnol. 2022 Jul;17(7):788-798. doi: 10.1038/s41565-022-01125-0. Epub 2022 May 23. Nat Nanotechnol. 2022. PMID: 35606443

5

Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.

Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, Hawkins GA, Soker S, Thomas KW, Miller LD, Lu Y, Bellinger CR, Zhang W, Habib AA, Petty WJ, Zhao D. Liu Y, et al. Nat Nanotechnol. 2022 Feb;17(2):206-216. doi: 10.1038/s41565-021-01032-w. Epub 2021 Dec 16. Nat Nanotechnol. 2022. PMID: 34916656 Free PMC article.

6

Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.

Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, Xu Y, Nam J, Xu J, Shi X, Wei L, Lei YL, Moon JJ. Sun X, et al. Nat Nanotechnol. 2021 Nov;16(11):1260-1270. doi: 10.1038/s41565-021-00962-9. Epub 2021 Sep 30. Nat Nanotechnol. 2021. PMID: 34594005 Free PMC article.

7

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy.

Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X, Liu G. Liu C, et al. Nat Nanotechnol. 2022 May;17(5):531-540. doi: 10.1038/s41565-022-01098-0. Epub 2022 Apr 11. Nat Nanotechnol. 2022. PMID: 35410368

8

Nanomaterials for T-cell cancer immunotherapy.

Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Gong N, et al. Nat Nanotechnol. 2021 Jan;16(1):25-36. doi: 10.1038/s41565-020-00822-y. Epub 2021 Jan 12. Nat Nanotechnol. 2021. PMID: 33437036 Review.

9

Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection.

Zhang J, Chen C, Li A, Jing W, Sun P, Huang X, Liu Y, Zhang S, Du W, Zhang R, Liu Y, Gong A, Wu J, Jiang X. Zhang J, et al. Nat Nanotechnol. 2021 May;16(5):538-548. doi: 10.1038/s41565-020-00843-7. Epub 2021 Feb 1. Nat Nanotechnol. 2021. PMID: 33526838

10

Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety.

Nguyen NT, Huang K, Zeng H, Jing J, Wang R, Fang S, Chen J, Liu X, Huang Z, You MJ, Rao A, Huang Y, Han G, Zhou Y. Nguyen NT, et al. Nat Nanotechnol. 2021 Dec;16(12):1424-1434. doi: 10.1038/s41565-021-00982-5. Epub 2021 Oct 25. Nat Nanotechnol. 2021. PMID: 34697491 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results